Highview Capital Management LLC DE Has $2.19 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Highview Capital Management LLC DE grew its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 6.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 24,507 shares of the medical equipment provider’s stock after buying an additional 1,439 shares during the period. Highview Capital Management LLC DE’s holdings in Boston Scientific were worth $2,189,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Catalyst Capital Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $97,000. AlphaCentric Advisors LLC bought a new position in Boston Scientific during the 4th quarter valued at $1,667,000. Sierra Ocean LLC purchased a new position in Boston Scientific during the 4th quarter worth $68,000. Monument Capital Management raised its holdings in shares of Boston Scientific by 7.5% in the fourth quarter. Monument Capital Management now owns 3,320 shares of the medical equipment provider’s stock valued at $297,000 after purchasing an additional 231 shares during the last quarter. Finally, J.W. Cole Advisors Inc. lifted its position in shares of Boston Scientific by 24.5% during the fourth quarter. J.W. Cole Advisors Inc. now owns 4,999 shares of the medical equipment provider’s stock valued at $447,000 after purchasing an additional 985 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on BSX. Sanford C. Bernstein increased their price objective on shares of Boston Scientific from $92.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. Royal Bank of Canada increased their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Mizuho boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Thursday, October 24th. JPMorgan Chase & Co. raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Monday, December 16th. Finally, Piper Sandler upped their price objective on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Boston Scientific has a consensus rating of “Buy” and an average target price of $107.39.

Boston Scientific Stock Performance

Shares of BSX stock opened at $106.20 on Monday. The firm has a market capitalization of $156.51 billion, a price-to-earnings ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average of $96.44 and a 200 day moving average of $88.29. Boston Scientific Co. has a 52 week low of $65.33 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. As a group, research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current year.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 6,389 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.06, for a total transaction of $671,228.34. Following the completion of the sale, the executive vice president now directly owns 24,293 shares in the company, valued at approximately $2,552,222.58. The trade was a 20.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the transaction, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 87,326 shares of company stock worth $8,673,948 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.